☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
P-III PRIME2
Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III PRIME2 Trial for the Treatment of Prurigo Nodularis
October 22, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.